Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Investigational Small-Molecule Drug Selectively Suppresses Constitutive CYP2B6 Activity at the Gene Transcription Level: Physiologically Based Pharmacokinetic Model Assessment of Clinical Drug Interaction Risk

Maciej J. Zamek-Gliszczynski, Michael A. Mohutsky, Jessica L. F. Rehmel and Alice B. Ke
Drug Metabolism and Disposition June 2014, 42 (6) 1008-1015; DOI: https://doi.org/10.1124/dmd.114.057018
Maciej J. Zamek-Gliszczynski
Drug Disposition, Lilly Research Laboratories, Indianapolis, Indiana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael A. Mohutsky
Drug Disposition, Lilly Research Laboratories, Indianapolis, Indiana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jessica L. F. Rehmel
Drug Disposition, Lilly Research Laboratories, Indianapolis, Indiana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alice B. Ke
Drug Disposition, Lilly Research Laboratories, Indianapolis, Indiana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Information

vol. 42 no. 6 1008-1015
DOI 
https://doi.org/10.1124/dmd.114.057018
PubMed 
24658455

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0090-9556
Online ISSN 
1521-009X
History 
  • Received January 13, 2014
  • Accepted March 19, 2014
  • Published online April 25, 2014.

Article Versions

  • Earlier version (March 21, 2014 - 07:24).
  • You are viewing the most recent version of this article.
Copyright & Usage 
Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Maciej J. Zamek-Gliszczynski,
  2. Michael A. Mohutsky,
  3. Jessica L. F. Rehmel, and
  4. Alice B. Ke
  1. Drug Disposition, Lilly Research Laboratories, Indianapolis, Indiana
  1. Address correspondence to:
    Dr. Maciej J. Zamek-Gliszczynski, Lilly Corporate Center, Indianapolis, IN 46285. E-mail: m_zamek-gliszczynski{at}lilly.com
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: August 2017 to March 2023

AbstractFullPdf
Aug 20171187
Sep 20175149
Oct 20171238
Nov 20170177
Dec 20175175
Jan 20185144
Feb 201853819
Mar 2018119011
Apr 2018312013
May 201844111
Jun 20184687
Jul 20180233
Aug 20180147
Sep 20185127
Oct 20183308
Nov 201813721
Dec 20181507
Jan 201903712
Feb 20192307
Mar 201911913
Apr 2019121118
May 20191586
Jun 201912610
Jul 20192017
Aug 20192023
Oct 20191615
Nov 20192216
Dec 20199139
Jan 202042411
Feb 202001410
Mar 20201168
May 20203145
Jun 20201722
Jul 20202501
Aug 20201534
Sep 20201022
Oct 20201926
Nov 20202145
Dec 20201931
Jan 20211866
Feb 20212373
Mar 20212543
Apr 20214136
May 20211142
Jun 20212032
Jul 20212447
Aug 20212452
Sep 2021742
Oct 20211030
Nov 20212063
Dec 20212213
Jan 2022723
Feb 2022722
Mar 2022315
Apr 20221050
May 20221023
Jun 20222221
Jul 202226322
Aug 20222736
Sep 20221451
Oct 20221836
Nov 20221611
Dec 20221429
Jan 20234573
Feb 20231735
Mar 20232211

PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 42 (6)
Drug Metabolism and Disposition
Vol. 42, Issue 6
1 Jun 2014
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Investigational Small-Molecule Drug Selectively Suppresses Constitutive CYP2B6 Activity at the Gene Transcription Level: Physiologically Based Pharmacokinetic Model Assessment of Clinical Drug Interaction Risk
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Xenobiotic Selectively Suppresses CYP2B6

Maciej J. Zamek-Gliszczynski, Michael A. Mohutsky, Jessica L. F. Rehmel and Alice B. Ke
Drug Metabolism and Disposition June 1, 2014, 42 (6) 1008-1015; DOI: https://doi.org/10.1124/dmd.114.057018

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Xenobiotic Selectively Suppresses CYP2B6

Maciej J. Zamek-Gliszczynski, Michael A. Mohutsky, Jessica L. F. Rehmel and Alice B. Ke
Drug Metabolism and Disposition June 1, 2014, 42 (6) 1008-1015; DOI: https://doi.org/10.1124/dmd.114.057018
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • A PBPK model for CBD in adults and children
  • rs2242480 Regulates the Expression of CYP3A4 and CYP3A5
  • Absorption, Metabolism, and Excretion of Taselisib
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics